TAHO Pharmaceuticals (6467.TW)

Executive Summary

TAHO Pharmaceuticals, headquartered in Taipei, Taiwan, is a publicly traded specialty pharmaceutical company (Ticker: 6467.TW) that focuses on developing innovative drug delivery technologies, particularly its proprietary Transepithelial Delivery System (TDS). This platform enables the creation of oral dissolving films, buccal films, and transdermal patches that enhance bioavailability, improve patient compliance, and provide safer administration of drugs across multiple therapeutic areas, including cardiovascular, neurology, oncology, and emergency medicine. By leveraging its TDS platform, TAHO addresses significant unmet needs in anticoagulation, opioid overdose reversal, ADHD, and chemotherapy-induced nausea, positioning itself as a leader in transmucosal and transdermal delivery. With a strong intellectual property portfolio and a growing pipeline of proprietary products, TAHO Pharmaceuticals is poised for growth through both internal development and strategic partnerships. The company's differentiated technology offers a competitive edge over traditional oral and injectable formulations, particularly in markets requiring rapid onset or improved ease of use. As TAHO advances its pipeline toward regulatory submissions and seeks to expand its commercial footprint through licensing deals, its focus on high-impact, patient-centric solutions presents a compelling opportunity in the specialty pharmaceutical space.

Upcoming Catalysts (preview)

• Q3 2026FDA NDA submission for lead opioid overdose reversal film75% success
• Q1 2027Licensing agreement with a major pharma for ADHD transdermal patch60% success
• H2 2026Positive Phase 3 results for chemotherapy-induced nausea film70% success